Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer

Jethwa, Krishan R.; Jang, Samuel; Mullikin, T.C.; Harmsen, William S.; Petersen, M.; Olivier, Kenneth R.; Park, Sean S.; Neben-Wittich, M.A.; Hubbard, Joleen M.; Sandhyavenu, Harigopal; Whitaker, Thomas J.; Waltman, Lindsey A.; Kipp, Benjamin R.; Merrell, Kenneth W.; Haddock, Michael G.; Hallemeier, Christopher L.

doi:10.1016/j.radonc.2020.02.008

Cited by 24 publications

(16 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Volume of metastases correlated with LC in 3 series 21,24,25 and with OS in 6 studies. 19,23,[25][26][27][28] Total number of metastases treated with SABR was not a clear prognostic factor according to our analysis. Limited number (< 3) of metastases improved LC in one study 29 and OS in two.…”

Section: Sabr-related Predictors Of Response In Primary Tumor-specific Oligometastatic Disease Colorectal Cancercontrasting

confidence: 65%

“…Advanced age was an unfavorable prognostic factor in oligometastases disease treated with SABR in 3 retrospective series. 17,22,26 The role of chemotherapy in CRC oligometastases treated with SABR is unclear. Thomson et al reported that number of lines of previous systemic therapy improved OS, 19 while it was a poor prognostic factor in Franzese et al analysis.…”

Section: Sabr-related Predictors Of Response In Primary Tumor-specific Oligometastatic Disease Colorectal Cancermentioning

confidence: 99%

“… PFS: -BRAF wild-type (p-value 0.046) N.A. Jethwa, 26 2020 Retrospective 85/109 58 Liver Lung Nodes Bone Other 50 Gy/ 3–5 fr 113 50 70% (2yrs) 69% (2yrs) 26% (5yrs) 14% (2yrs) 5% (5yrs) OS: -age > 60 years (HR: 2.4, p-value 0.01) LC: -KRAS and TP53 mutation (HR: 4.5, p-value 0.04) OS: -lesion size per 1 cm (HR: 1.3, p-value < 0.01) -KRAS mutation (HR: 2.2, p-value < 0.01) N.A. Hoyer, 30 2006 Prospective 64/141 67 Liver (69%) Lung (19%) Others (12%) 45 Gy/ 3 fr N.A.…”

Section: Sabr-related Predictors Of Response In Primary Tumor-specific Oligometastatic Diseasementioning

confidence: 99%

See 2 more Smart Citations

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer

Franceschini

Teriaca

Dominici

et al. 2021

CMAR

View full text Add to dashboard Cite

Oligometastatic patients are a heterogeneous and yet not well-defined population. The actual definition identifies as oligometastatic, patients with 1-5 metastases in 1-3 different organs. However, only a proportion of these patients are "true" oligometastatic and therefore derive some kinds of benefit from local ablative approaches like stereotactic ablative radiation therapy (SABR). Since SABR is an easily accessible, effective and welltolerated treatment, it is widely employed in the oligometastatic scenarios, without a particular focus on selection criteria. However, it should be crucial to identify predictive and prognostic features that could be clinically implemented. Therefore, we conducted this narrative review of the available literature to summarize all clinical, radiomic, genetic and epigenetic features found to be predictive of overall survival, progression-free survival or local control of oligometastatic patients treated with SABR.

show abstract

Section: Sabr-related Predictors Of Response In Primary Tumor-specific Oligometastatic Disease Colorectal Cancercontrasting

confidence: 65%

Section: Sabr-related Predictors Of Response In Primary Tumor-specific Oligometastatic Disease Colorectal Cancermentioning

confidence: 99%

Section: Sabr-related Predictors Of Response In Primary Tumor-specific Oligometastatic Diseasementioning

confidence: 99%

See 1 more Smart Citation

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer

Franceschini

Teriaca

Dominici

et al. 2021

CMAR

View full text Add to dashboard Cite

show abstract

“…In a randomised phase II trial of proton therapy for liver metastases KRAS mutants and TP53 mutants had worse local control than wild type patients [24]. A recent comprehensive study of tumour mutation status in a multisite cohort [27] demonstrated similar findings. Interestingly, although only 10% of their cohort, NM had 100% LC at 2 years.…”

Section: Nodal Oligometastatic Colorectal Cancer and Sbrtmentioning

confidence: 83%

Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy

O’Cathail

Smith

Owens

et al. 2020

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…At present, the investigations on oligo-metastasis genes are mainly focused on liver oligo-metastatic colorectal cancer (CRC). There is a trend towards a higher risk of local failure for lesions with TP53 mutation and KRAS mutation for CRC patients who received metastasis-directed stereotactic body radiation therapy [23]. In addition, for CRC patients treated with liver ablation, a well-established local therapy modality routinely utilized in the oligo-metastatic disease setting, RAS mutation is also a prognosticator of shorter local tumor progression free survival [24].…”

Section: Discussionmentioning

confidence: 99%

Genetic Analysis of Oligo-Metastatic Breast Cancer: Correlation with Clinicopathological Features

Jiang

Zhou

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: We aimed to identify the relationship between the genomic characteristics and clinicopathological features of oligo-metastatic breast cancer.Methods: Oligo-metastatic breast cancer diagnosed by pathology from January 2001 and August 2019 were identified and we matched the poly-metastatic patients based on the clinicopathological features of the oligo-metastatic patients included. The database of all genomic alterations was shown according to the FoundationOne CDx reports. Clinicopathological characteristics were collected and the results of next-generation sequencing were analyzed.Results: A total of 26 breast cancer patients were enrolled in our study, including 14 patients with oligo-metastatic disease and 12 patients with poly-metastatic disease. There was no significant difference in number of gene alteration, tumor mutational burden, variants of unknown significance (VUS), and actional mutation in oligo- and poly-metastasis. PIK3CA, TP53 and ERBB2 were the most common shared alterations identified in patients included. Based on the median time of oligo-progression disease (oligo-PD), we divided the patients with oligo-metastasis into longer oligo-PD group (oligo-PD > 31.04 months) and shorter oligo-PD group (oligo-PD ≤ 31.04 months). The analysis of PIK3CA mutation sites showed that H1047R was associated with a good prognosis in patients with metastatic breast cancer. HER2 positive patients with oligo-metastasis was more likely to have a good prognosis. In addition, VUS might also be a potential prognostic biomarker in metastatic breast cancer. Conclusion: Through the genetic analysis of oligo-metastasis, we found PIK3CA H1047R, HER2 and VUS might predict the different clinical outcomes of breast cancer patients with oligo-metastasis for the individualized treatment.

show abstract

Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer

Cited by 24 publications

References 44 publications

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer

Knowing When to Use Stereotactic Ablative Radiation Therapy in Oligometastatic Cancer

Superior outcomes of nodal metastases compared to visceral sites in oligometastatic colorectal cancer treated with stereotactic ablative radiotherapy

Genetic Analysis of Oligo-Metastatic Breast Cancer: Correlation with Clinicopathological Features

Contact Info

Product

Resources

About